Oncopremium Team S.R.L.
- Address
- lock Available on a paid plan
Small-Cell Lung Cancer (SCLC)
The site focuses on small-cell lung cancer research, evaluating new therapeutic combinations to improve patient survival.
- Immunotherapy plus chemotherapy regimens
- Lurbinectedin as single agent or with Irinotecan
- Management of relapsed disease after platinum failure
- Assessment of overall survival outcomes
Oncopremium Team S.R.L. conducts these trials in Baia Mare, aiming to advance treatment options for this aggressive cancer.
First-line Extensive-Stage Small-Cell Lung Cancer (ES‑SCLC)
Studies target first‑line treatment of extensive-stage small-cell lung cancer, comparing novel immune‑checkpoint inhibitors with standard chemotherapy.
- Pembrolizumab combined with chemotherapy
- Progression‑free survival as a primary endpoint
- Enrollment based on PD‑L1 CPS ≥1
- Blinded independent central radiologic review
The research seeks to establish more effective first‑line regimens for patients who have not received prior chemotherapy.
HR+/HER2‑ Negative Locally Recurrent Inoperable or Metastatic Breast Cancer
Clinical work at the center includes trials for HR+/HER2‑ negative breast cancer, testing immunotherapy added to chemotherapy in patients without prior cytotoxic treatment.
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy
- Evaluation of overall survival benefit
- Biomarker‑driven patient selection
- Focus on non‑curative disease setting
The oncology department leverages its expertise to improve outcomes for breast cancer patients across Romania.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1BioNTech SE1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oncopremium Team S.R.L.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer | BioNTech SE | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alpelisib | 1 | Unknown | 2023-06-06 | 2023-06-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.